Targeting Severe Asthma and Nasal Polyps Together with Monoclonal Antibodies

Severe asthma and nasal polyps often coexist, driven by similar immune pathways. Traditional therapies—high-dose inhaled steroids, oral steroids, surgeries for polyps—can help, but many patients still struggle with frequent flare-ups, breathing difficulties, chronic nasal congestion and reduced quality of life. Monoclonal antibodies (mAbs) offer a targeted approach, dialing down specific molecules in the immune system to control both asthma and nasal polyps.

Why Combine Treatment for Asthma and Polyps?

• Shared inflammation: Both conditions often involve eosinophils (a type of white blood cell) and type 2 immunity (IL-4, IL-5, IL-13).
• Dual benefits: One therapy can reduce asthma exacerbations, improve lung function, shrink or prevent regrowth of polyps.
• Steroid‐sparing: Decreases reliance on oral steroids, lowering long-term side effects (bone thinning, weight gain, mood changes).

If you're experiencing frequent wheezing, chest tightness or chronic nasal blockage, use Ubie's free AI-powered Bronchial Asthma symptom checker to help you understand your symptoms before speaking with your doctor.

Overview of Key Monoclonal Antibodies

1. Omalizumab

   • Target: Immunoglobulin E (IgE)
   • Indications: Allergic (IgE-mediated) asthma; some benefit for nasal polyps
   • Administration: Subcutaneous every 2–4 weeks
   • Biomarker: Total IgE levels and skin prick tests

2. Mepolizumab and Reslizumab

   • Target: Interleukin-5 (IL-5)
   • Indications: Eosinophilic asthma; mepolizumab also approved for nasal polyps
   • Administration:
     • Mepolizumab: Subcutaneous every 4 weeks
     • Reslizumab: Intravenous every 4 weeks
   • Biomarker: Blood eosinophil count ≥150–300 cells/µL

3. Benralizumab

   • Target: IL-5 receptor α
   • Indications: Eosinophilic asthma; emerging evidence for nasal polyps
   • Administration: Subcutaneous every 4 weeks (first 3 doses), then every 8 weeks
   • Biomarker: Blood eosinophil count

4. Dupilumab

   • Target: IL-4 receptor α (blocks IL-4 & IL-13 signaling)
   • Indications: Type 2 asthma; moderate‐to‐severe nasal polyps
   • Administration: Subcutaneous every 2 weeks
   • Biomarkers: Elevated FeNO (≥25 ppb), eosinophils, atopic markers

5. Tezepelumab

   • Target: Thymic stromal lymphopoietin (TSLP)
   • Indications: Broad severe asthma, regardless of eosinophil count; potential for polyps
   • Administration: Subcutaneous every 4 weeks
   • Biomarkers: None strictly required

Who Is a Good Candidate?

• History of severe asthma with frequent exacerbations despite high-dose inhaled steroids and controllers
• Documented nasal polyps causing significant nasal obstruction, anosmia or facial pressure
• Elevated biomarkers (eosinophils, IgE, FeNO) aligning with mAb mechanism
• Multiple oral steroid courses in the past year or steroid-related side effects
• Willingness to self-inject or attend regular infusion visits

Clinical Benefits

• Reduction in asthma exacerbations (up to 50–70% in trials)
• Improved lung function (FEV₁ increases of 200–400 mL on average)
• Fewer hospitalizations and emergency visits
• Shrinkage of nasal polyps and improved sense of smell
• Better symptom control: less wheezing, breathlessness, nasal congestion, runny nose
• Lower cumulative steroid dose over time

Real-World Impact

Patients often report:

• Easier breathing during daily activities and exercise
• Fewer missed work or school days
• Enhanced sleep quality (less nighttime coughing, sneezing)
• Improved mood and energy levels

Safety and Side Effects

Most monoclonal antibodies are well tolerated. Common, mild reactions include:

• Injection‐site redness, swelling or itching
• Headache, fatigue, muscle aches
• Rare: allergic reactions—inform your doctor immediately if you develop hives, facial swelling, difficulty breathing

Long-term safety profiles are reassuring, but ongoing monitoring by your healthcare team is essential.

Practical Considerations

1. Administration
   • Many are approved for at-home self-injection after training
   • Some require clinic visits for infusions
2. Insurance and Cost
   • High cost per dose; insurance coverage or patient assistance programs often available
   • Prior authorization by insurers may be required
3. Monitoring Response
   • Regular follow-ups (every 3–6 months) to assess symptom control, lung function, polyp status
   • Biomarker checks (eosinophils, FeNO) guide ongoing therapy
4. Combination with Standard Therapy
   • Continue inhaled corticosteroids and bronchodilators as prescribed
   • Use nasal corticosteroid sprays or rinses for polyp management

What to Expect When Starting Monoclonal Antibodies

• Initial assessment: blood work (eosinophils, IgE), lung function tests, nasal endoscopy or CT scan for polyps
• Education on injection technique, storage, side-effect recognition
• First doses often given under medical supervision to monitor any immediate reactions
• Gradual improvement over 4–12 weeks; maximal benefits may appear by 6 months

Ongoing Research and Future Directions

• New targets: IL-33, CCR3 inhibitors, anti-TSLP combinations
• Personalized treatment: genetic and biomarker profiling to predict best mAb choice
• Long-term disease modification: aiming not just for symptom control, but remission

Next Steps for Patients

1. Track your symptoms: asthma diary, polyp-related nasal symptoms, quality of life
2. Discuss monoclonal antibodies with your respiratory specialist or ENT doctor
3. Verify insurance coverage and explore financial assistance programs
4. Train in self-injection if eligible, or schedule infusion appointments
5. Maintain standard inhaler and nasal spray therapies

Not sure if your respiratory symptoms require specialist care? Take a few minutes to complete Ubie's free Bronchial Asthma symptom checker and get personalized insights to share with your healthcare provider.

When to Speak to a Doctor

• Sudden worsening of breathing or chest tightness
• Severe nasal obstruction or pain in your face
• Signs of an allergic reaction to treatment (hives, swelling, difficulty breathing)
• Any life-threatening or serious symptoms

Monoclonal antibodies for severe asthma and polyps together represent a major advance. By targeting the specific drivers of inflammation, these therapies can improve both breathing and quality of life, while reducing the need for high-dose steroids. Always work closely with your healthcare team to determine the best treatment plan and ensure safe, effective use.